Ecstasy and Neurodegeneration

Overview

Journal BMJ

Specialty General Medicine

Date 1996 Jun 15

PMID 8646128

Citations 10

Authors

A R Green

G M Goodwin

Affiliations

Soon will be listed here.

Citing Articles

Attenuates MDMA-Induced Neuroinflammation in the CA1 Region of the Hippocampus in the Rat Model.

Olatunji S, Okoro I, Owolabi J, Olanrewaju J, Adelodun S, Fabiyi S Ann Neurosci. 2021; 27(3-4):104-113.

PMID: 34556948 PMC: 8455002. DOI: 10.1177/0972753120966852.

Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Green A, King M, Shortall S, Fone K Br J Pharmacol. 2011; 166(5):1523-36.

PMID: 22188379 PMC: 3419898. DOI: 10.1111/j.1476-5381.2011.01819.x.

Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats.

Blessing W, Seaman B, Pedersen N, Ootsuka Y J Neurosci. 2003; 23(15):6385-91.

PMID: 12867524 PMC: 6740548.

Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.

de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R, Roset P Br J Clin Pharmacol. 2000; 49(2):104-9.

PMID: 10671903 PMC: 2014905. DOI: 10.1046/j.1365-2125.2000.00121.x.

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Huether G, Zhou D, Ruther E J Neural Transm (Vienna). 1997; 104(8-9):771-94.

PMID: 9451711 DOI: 10.1007/BF01285547.

References

Ricaurte G, FORNO L, Wilson M, DELANNEY L, Irwin I, Molliver M . (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA. 1988; 260(1):51-5. View

Langston J, Ballard P, Tetrud J, Irwin I . Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983; 219(4587):979-80. DOI: 10.1126/science.6823561. View

Colado M, Green A . The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol. 1995; 280(3):343-6. DOI: 10.1016/0014-2999(95)00298-y. View

Colado M, Williams J, Green A . The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol. 1995; 115(7):1281-9. PMC: 1908797. DOI: 10.1111/j.1476-5381.1995.tb15037.x. View

Przedborski S, Kostic V, Jackson-Lewis V, Naini A, Simonetti S, Fahn S . Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci. 1992; 12(5):1658-67. PMC: 6575882. View

Green A, Cross A, Goodwin G . Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berl). 1995; 119(3):247-60. DOI: 10.1007/BF02246288. View

McCann U, Ridenour A, Shaham Y, Ricaurte G . Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans. Neuropsychopharmacology. 1994; 10(2):129-38. DOI: 10.1038/npp.1994.15. View

Vingerhoets F, Snow B, Tetrud J, Langston J, Schulzer M, Calne D . Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann Neurol. 1994; 36(5):765-70. DOI: 10.1002/ana.410360513. View

McGuire P, Cope H, Fahy T . Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamine ('Ecstasy'). Br J Psychiatry. 1994; 165(3):391-5. DOI: 10.1192/bjp.165.3.391. View

10.

Fischer C, Hatzidimitriou G, Wlos J, Katz J, Ricaurte G . Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurosci. 1995; 15(8):5476-85. PMC: 6577639. View

11.

. New Targets for Long Acting Drugs Involving Translocation to the Nucleus. Proceedings of the 6th Biochemical Pharmacology Symposium. Oxford, 22-23 July 1993. Dedicated to Professor Peter Alexander PhD, Dsc. 1922-1993. Biochem Pharmacol. 1994; 47(1):1-154. View